Clinical trials for patients with non-cancerous blood disorders.
If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a Clinical Trial page for referral information.
For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.
Clinical Trials Enquiry Coordinator
Business hours, Mon to Friday between 9am - 2pm
Email [email protected]
Phone (03) 8559 7456
Open and Recruiting Clinical Trials
A clinical to test if the treatment Ravulizumab is best given as an injection into the skin or into a vein for patients who have Paroxysmal Nocturnal Hemoglobinuria and are currently being treated with the treatment Eculizumab
Non malignant blood disorder (not a cancer) Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open and recruiting
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.
Patients with PNH are currently treated with the standard treatment Eculizumab. This clinical trial aims to see if an alternative treatment called Ravulizumab is as effective and if an injection into the skin or into a vein is most effective.
Who can participate
- Have PNH who are currently being treated with Eculizumab
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.